GSK's Jemperli (dostarlimab) Receives the EC's Approval for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer
Shots:
- The EC has granted conditional approval for Jemperli in women with dMMR/ MSI-H endometrial cancer that has progressed on or following prior treatment with a Pt.- containing regimen
- AnaptysBio has received $10M as milestones upon the EC’s approval and will receive $35M as regulatory milestones in the US & EU- $165M as sales milestones following achievement of annual sales revenues with royalties range from 8% to 25% of global sales
- GSK and AnaptysBio continue to develop Abs including cobolimab and GSK4074386. AnaptysBio will receive milestones for each of the first two indications of Abs and is eligible to receive ~$1.1B in milestones with royalties ranging from 4% to 8% on global net sales of Abs and 1% of GSK’s global sales of Zejula
Ref: Globe Newswire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com